Konig H - Search Results

1

Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML.

Sayar H, Liu Y, Gao R, Zaid MA, Cripe LD, Weisenbach J, Sargent KJ, Nassiri M, Li L, Konig H, Suvannasankha A, Pan F, Shanmugam R, Goswami C, Kapur R, Xu M, Boswell HS. Sayar H, et al. Among authors: konig h. Oncotarget. 2017 Dec 25;9(5):5703-5715. doi: 10.18632/oncotarget.23655. eCollection 2018 Jan 19. Oncotarget. 2017. PMID: 29464028 Free PMC article.

2

Pilot study of erlotinib in patients with acute myeloid leukemia.

Sayar H, Czader M, Amin C, Cangany M, Konig H, Cripe LD. Sayar H, et al. Among authors: konig h. Leuk Res. 2015 Feb;39(2):170-2. doi: 10.1016/j.leukres.2014.11.022. Epub 2014 Dec 2. Leuk Res. 2015. PMID: 25498508

3

Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.

Sayar H, Cripe LD, Saliba AN, Abu Zaid M, Konig H, Boswell HS. Sayar H, et al. Among authors: konig h. Leuk Res. 2019 Feb;77:30-33. doi: 10.1016/j.leukres.2018.12.011. Epub 2018 Dec 24. Leuk Res. 2019. PMID: 30626561 Free article. No abstract available.

4

Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia.

Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, Zaid MA, Farag SS, Konig H. Agrawal V, et al. Among authors: konig h. Curr Cancer Drug Targets. 2020;20(7):473-489. doi: 10.2174/1568009620666200502011059. Curr Cancer Drug Targets. 2020. PMID: 32357813 Review.

5

Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications.

Chen F, Wu X, Niculite C, Gilca M, Petrusca D, Rogozea A, Rice S, Guo B, Griffin S, Calin GA, Boswell HS, Konig H. Chen F, et al. Among authors: konig h. J Cell Mol Med. 2020 Jul;24(13):7378-7392. doi: 10.1111/jcmm.15339. Epub 2020 May 25. J Cell Mol Med. 2020. PMID: 32450611 Free PMC article.

6

Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions.

Chen F, Licarete E, Wu X, Petrusca D, Maguire C, Jacobsen M, Colter A, Sandusky GE, Czader M, Capitano ML, Ropa JP, Boswell HS, Carta F, Supuran CT, Parkin B, Fishel ML, Konig H. Chen F, et al. Among authors: konig h. J Cell Mol Med. 2021 Dec;25(24):11039-11052. doi: 10.1111/jcmm.17027. Epub 2021 Nov 17. J Cell Mol Med. 2021. PMID: 34791807 Free PMC article.

7

The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.

Chang E, Ganguly S, Rajkhowa T, Gocke CD, Levis M, Konig H. Chang E, et al. Among authors: konig h. Leukemia. 2016 May;30(5):1025-32. doi: 10.1038/leu.2015.346. Epub 2015 Dec 21. Leukemia. 2016. PMID: 26686245 Free PMC article.

8

Treatment of Acute Myeloid Leukemia in the Era of Genomics-Achievements and Persisting Challenges.

Green SD, Konig H. Green SD, et al. Among authors: konig h. Front Genet. 2020 May 27;11:480. doi: 10.3389/fgene.2020.00480. eCollection 2020. Front Genet. 2020. PMID: 32536937 Free PMC article. Review.

9

Signal transduction in Acute Myeloid Leukemia - Implications for Novel Therapeutic Concepts.

Konig H, Santos CD. Konig H, et al. Curr Cancer Drug Targets. 2015;15(9):803-21. doi: 10.2174/1568009615666150817104916. Curr Cancer Drug Targets. 2015. PMID: 26278711 Review.

10

The rocky road to personalized medicine in acute myeloid leukaemia.

Brinda B, Khan I, Parkin B, Konig H. Brinda B, et al. Among authors: konig h. J Cell Mol Med. 2018 Mar;22(3):1411-1427. doi: 10.1111/jcmm.13478. Epub 2018 Jan 12. J Cell Mol Med. 2018. PMID: 29327808 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,480 results

Search Page